ACM
PACB icon

Altium Capital Management’s Pacific Biosciences PACB Stock Holding History

Altium Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-178,000
Closed -$2.06M – 87
2023
Q1 		$2.06M Sell
178,000
-187,000
-51% -$1.86M 1.14% 33
2022
Q4 		$2.99M Buy
+365,000
New +$3.14M 1.52% 27

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Altium Capital Management's PACB Position: Q2 2023 in Review

Altium Capital Management sold out of Pacific Biosciences (PACB) in Q2 2023, closing a stake of 178,000 shares — an estimated $2.06M sold.

Altium Capital Management first reported a position in PACB in Q4 2022 and held it in 2 quarters. The position peaked at $2.99M in Q4 2022. 272 funds tracked by Wall St. Rank hold PACB as of Q2 2023.

  • Altium Capital Management reported no remaining Pacific Biosciences position as of Q2 2023 after selling out during the quarter.
  • Altium Capital Management sold 178,000 Pacific Biosciences shares in Q2 2023, an estimated $2.06M.
  • Altium Capital Management first reported a position in Pacific Biosciences in Q4 2022 and held it in 2 quarters.
  • Altium Capital Management's Pacific Biosciences position peaked at $2.99M in Q4 2022.
  • 272 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2023.

Based on Altium Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.